small molecule

REXULTI

BREXPIPRAZOLE

Loss of exclusivityApril 2033latest FDA-listed patent expiry

CompanyOtsuka Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand name	REXULTI
Active ingredient	BREXPIPRAZOLE
Strength	2MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	July 2015
Marketing status	RX

Listed patents

Patent	Expires	Type
10307419*PED	April 2033	—
10307419	October 2032	product
RE48059*PED	June 2029	—
RE48059	December 2028	substance
9839637*PED	October 2026	—
8618109*PED	October 2026	—
8349840*PED	October 2026	—
8349840	April 2026	product
9839637	April 2026	product
8618109	April 2026	use U-3281

Regulatory exclusivity

Code	Expires
M-315	May 2028
PED	November 2027
M-14	May 2027
PED	November 2026
I-913	May 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Otsuka Pharmaceutical